Start free

Electra Therapeutics, Inc. (ETRA) insider trading

Recent insider transactions reported to the SEC on Form 4 — directors and officers buying or selling their own company’s stock. Sourced directly from public SEC filings, latest filed Nov 10, 2026.

Filings shown
10
Open-market buys
36
Open-market sells
0
Buys, 10b5-1 box not checked
36 of 36

Counts cover the 10 most recent Form 4 filings Tradune holds for ETRA (filed Sep 21 – Nov 10, 2026). SEC EDGAR Form 4 filings for ETRA last checked Nov 21, 2026, 09:00 UTC; the latest ETRA filing Tradune holds was filed Nov 10, 2026. This is not guaranteed to be the complete record — see ETRA's full Form 4 filing history on SEC EDGAR.

Open-market activity, last 90 days

Purchases (Form 4 code P) and sales (code S) on the 10 filings Tradune holds for ETRA filed Sep 21 – Nov 10, 2026. Grants, exercises, tax withholding and the other Form 4 transaction codes are left out.

Open-market purchases and sales by insider
Insider Buys Sells Shares bought Shares sold Value
Carl L. GordonDirector, 10% owner 18 0 1,898,020 — +$24,349,642
Orbimed Advisors LLCDirector, 10% owner 18 0 1,898,020 — +$24,349,642

Value = shares × the price reported on each Form 4 (+ purchases, − sales); every open-market line in this window disclosed a price.

Insider-activity score

56/ 100

Net insider purchases
1 distinct buyer18 buy · 0 sell txofficer buying

Summarises ~90 days of public SEC Form 4 activity — more distinct buyers, officer involvement and net buying score higher. A description of filing activity, not a rating or buy signal. How this score is computed →

Get alerted when insiders buy the stocks you own

Add your holdings — no brokerage login — and Insider Radar sends a Telegram alert when an open-market Form 4 buy of $100,000 or more is filed on a stock you hold or watch.

Free for everyone right now · no card · nothing to buy

Start free

Weekly signal history

ETRA appeared in 1 archived weekly edition as a multi-insider cluster, a top net buyer, or both. These are frozen weekly snapshots, not a complete filing history.

  1. Week of Nov 10, 2026
    2 insiders buying · $7,210,233 net

An entry means this company met that edition’s displayed cluster or top-buyer threshold. Missing weeks do not mean no insider transaction occurred. All figures are derived from SEC Form 4 filings; open-market buys minus sales are shown as net only when every transaction value was disclosed.

How to read this: an open-market purchase (Form 4 code P) is a buy at the market price with the insider’s own money, as opposed to a grant, award or option exercise; an open-market sale is code S. When two or more distinct insiders report open-market purchases in the same 90-day window, this site labels that a cluster — a definition, not a forecast; see insider cluster buying. “Held after” is Form 4 Table I column 5; “Change” = shares ÷ holdings before the trade (held after − shares for an acquisition, held after + shares for a disposition).

Insider Buying at ETRA

Insiders reported 36 open-market purchases of ETRA in the trailing 90 days, across 2 distinct buyers. The most recent purchase was reported by Orbimed Advisors LLC (Director, 10% owner) on Nov 10, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Recent Form 4 filings

Source: SEC EDGAR Form 4 · transaction codes explained

Carl L. Gordon Director, 10% owner · filed Nov 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 20,700 $8.45 5,255,278 (indirect) +0.4% Nov 10, 2026
Open-market purchase 10b5-1 box not checked 2,000 $8.45 2,194,579 (indirect) +0.1% Nov 10, 2026
Open-market purchase 10b5-1 box not checked 4,000 $8.24 5,234,578 (indirect) +0.1% Nov 9, 2026
Open-market purchase 10b5-1 box not checked 16,000 $8.24 2,192,579 (indirect) +0.7% Nov 9, 2026
Open-market purchase 10b5-1 box not checked 9,816 $7.85 5,230,578 (indirect) +0.2% Nov 6, 2026
Open-market purchase 10b5-1 box not checked 39,600 $7.85 2,176,579 (indirect) +1.9% Nov 6, 2026

† change in this filer’s own reported holding line (Form 4 Table I, col. 5), not of total company ownership; small prior holdings produce large percentages, so under 100 shares the prior holding is shown instead.

“10b5-1 box checked” = the filer checked the Form 4 box stating that a transaction on the filing was made under a plan intended to satisfy Rule 10b5-1(c); “10b5-1 box not checked” = the box was left blank, which does not prove that no plan exists. The box applies to Form 4s filed from April 1, 2023; older filings, and boxes we could not read, carry no tag. What the 10b5-1 box means.

Orbimed Advisors LLC Director, 10% owner · filed Nov 10, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 2,000 $8.45 2,194,579 (indirect) +0.1% Nov 10, 2026
Open-market purchase 10b5-1 box not checked 20,700 $8.45 5,255,278 (indirect) +0.4% Nov 10, 2026
Open-market purchase 10b5-1 box not checked 4,000 $8.24 5,234,578 (indirect) +0.1% Nov 9, 2026
Open-market purchase 10b5-1 box not checked 16,000 $8.24 2,192,579 (indirect) +0.7% Nov 9, 2026
Open-market purchase 10b5-1 box not checked 9,816 $7.85 5,230,578 (indirect) +0.2% Nov 6, 2026
Open-market purchase 10b5-1 box not checked 39,600 $7.85 2,176,579 (indirect) +1.9% Nov 6, 2026
Carl L. Gordon Director, 10% owner · filed Nov 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 30,891 $7.31 5,220,762 (indirect) +0.6% Nov 5, 2026
Open-market purchase 10b5-1 box not checked 125,200 $7.31 2,136,979 (indirect) +6.2% Nov 5, 2026
Open-market purchase 10b5-1 box not checked 37,100 $7.78 1,991,779 (indirect) +1.9% Nov 4, 2026
Open-market purchase 10b5-1 box not checked 20,000 $7.07 2,011,779 (indirect) +1.0% Nov 4, 2026
Open-market purchase 10b5-1 box not checked 9,267 $7.78 5,184,871 (indirect) +0.2% Nov 4, 2026
Open-market purchase 10b5-1 box not checked 5,000 $7.07 5,189,871 (indirect) +0.1% Nov 4, 2026
Open-market purchase 10b5-1 box not checked 97,800 $7.84 1,856,079 (indirect) +5.6% Nov 3, 2026
Open-market purchase 10b5-1 box not checked 24,313 $7.84 5,151,204 (indirect) +0.5% Nov 3, 2026
Open-market purchase 10b5-1 box not checked 24,400 $7.88 5,175,604 (indirect) +0.5% Nov 3, 2026
Open-market purchase 10b5-1 box not checked 98,600 $7.88 1,954,679 (indirect) +5.3% Nov 3, 2026
Orbimed Advisors LLC Director, 10% owner · filed Nov 5, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Open-market purchase 10b5-1 box not checked 30,891 $7.31 5,220,762 (indirect) +0.6% Nov 5, 2026
Open-market purchase 10b5-1 box not checked 125,200 $7.31 2,136,979 (indirect) +6.2% Nov 5, 2026
Open-market purchase 10b5-1 box not checked 9,267 $7.78 5,184,871 (indirect) +0.2% Nov 4, 2026
Open-market purchase 10b5-1 box not checked 37,100 $7.78 1,991,779 (indirect) +1.9% Nov 4, 2026
Open-market purchase 10b5-1 box not checked 5,000 $7.07 5,189,871 (indirect) +0.1% Nov 4, 2026
Open-market purchase 10b5-1 box not checked 20,000 $7.07 2,011,779 (indirect) +1.0% Nov 4, 2026
Open-market purchase 10b5-1 box not checked 24,313 $7.84 5,151,204 (indirect) +0.5% Nov 3, 2026
Open-market purchase 10b5-1 box not checked 97,800 $7.84 1,856,079 (indirect) +5.6% Nov 3, 2026
Open-market purchase 10b5-1 box not checked 24,400 $7.88 5,175,604 (indirect) +0.5% Nov 3, 2026
Open-market purchase 10b5-1 box not checked 98,600 $7.88 1,954,679 (indirect) +5.3% Nov 3, 2026
Carl L. Gordon Director, 10% owner · filed Sep 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative Series C Convertible Preferred Stock 758,279 — — — Sep 21, 2026
Conversion of derivative 1,087,934 — 3,090,244 (indirect) +54% Sep 21, 2026
Conversion of derivative 1,703,314 — 4,793,558 (indirect) +55% Sep 21, 2026
Open-market purchase 10b5-1 box not checked 333,333 $15.00 5,126,891 (indirect) +7.0% Sep 21, 2026
Conversion of derivative 758,279 — 758,279 (indirect) — Sep 21, 2026
Open-market purchase 10b5-1 box not checked 1,000,000 $15.00 1,758,279 (indirect) +132% Sep 21, 2026
Conversion of derivative Series A Convertible Preferred Stock 2,002,310 — — — Sep 21, 2026
Conversion of derivative Series B Convertible Preferred Stock 1,087,934 — — — Sep 21, 2026
Conversion of derivative Series C Convertible Preferred Stock 1,703,314 — — — Sep 21, 2026
Conversion of derivative 2,002,310 — 2,002,310 (indirect) — Sep 21, 2026
Orbimed Advisors LLC Director, 10% owner · filed Sep 23, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 2,002,310 — 2,002,310 (indirect) — Sep 21, 2026
Conversion of derivative 1,087,934 — 3,090,244 (indirect) +54% Sep 21, 2026
Conversion of derivative 1,703,314 — 4,793,558 (indirect) +55% Sep 21, 2026
Open-market purchase 10b5-1 box not checked 333,333 $15.00 5,126,891 (indirect) +7.0% Sep 21, 2026
Conversion of derivative 758,279 — 758,279 (indirect) — Sep 21, 2026
Open-market purchase 10b5-1 box not checked 1,000,000 $15.00 1,758,279 (indirect) +132% Sep 21, 2026
Conversion of derivative Series A Convertible Preferred Stock 2,002,310 — — — Sep 21, 2026
Conversion of derivative Series B Convertible Preferred Stock 1,087,934 — — — Sep 21, 2026
Conversion of derivative Series C Convertible Preferred Stock 1,703,314 — — — Sep 21, 2026
Conversion of derivative Series C Convertible Preferred Stock 758,279 — — — Sep 21, 2026
Graham Parry Chief Scientific Officer · filed Sep 21, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 85,504 — 85,504 — Sep 21, 2026
Conversion of derivative Series A Convertible Preferred Stock 85,504 — — — Sep 21, 2026
Gary S. Koe Chief Technical Officer · filed Sep 21, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 63,656 — 63,656 — Sep 21, 2026
Conversion of derivative Series A Convertible Preferred Stock 63,656 — — — Sep 21, 2026
Quehuong (Kathy) Dong President & CEO · filed Sep 21, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative 455,484 — 455,484 — Sep 21, 2026
Conversion of derivative Series A Convertible Preferred Stock 455,484 — — — Sep 21, 2026
Nancy Stagliano Director · filed Sep 21, 2026 · SEC ↗
TransactionSharesPriceHeld afterChange†Date
Conversion of derivative Series A Convertible Preferred Stock 255,635 — — — Sep 21, 2026
Conversion of derivative 255,635 — 255,635 — Sep 21, 2026

Insider filings reported around the same time

Other companies whose most recent Form 4 was filed closest to ETRA's (Nov 10, 2026).

Frequently asked about ETRA insider activity

How many insiders bought ETRA stock in the last 90 days?

2 distinct insiders at Electra Therapeutics, Inc. reported 36 open-market purchases (Form 4 code P) of ETRA shares in the trailing 90 days, the most recent filed by Orbimed Advisors LLC (Director, 10% owner) on Nov 10, 2026. Grants, option exercises, and tax-withholding transactions are excluded from these counts.

Who filed the most recent Form 4 for ETRA?

The most recent Form 4 on this page was filed by Orbimed Advisors LLC (Director, 10% owner) on Nov 10, 2026, reporting 6 transactions. The original document is linked from the filing list above on SEC EDGAR. Amended filings (Form 4/A) may later revise reported figures.

What was the largest open-market ETRA insider purchase shown?

The largest open-market purchase among the filings shown was 1,000,000 ETRA shares at $15.00 (about $15,000,000) by Carl L. Gordon (Director, 10% owner) on Sep 21, 2026. Value is shares × the price reported on the Form 4; its Rule 10b5-1 box is not checked.

Do the recent ETRA insider purchases have the Form 4 10b5-1 box checked?

No. All 36 ETRA open-market purchases shown were reported with the Rule 10b5-1 box not checked. A blank box records what the filer disclosed; it does not prove that no plan exists. Latest: Orbimed Advisors LLC (Director, 10% owner) on Nov 10, 2026, 20,700 shares.

New to Form 4s? The transaction codes, the 90-day window and the 0–100 score are defined on the insider-activity score methodology page.

Get insider alerts for ETRA — and your whole portfolio

Tradune watches SEC Form 4 filings and flags insider-cluster buying across everything you hold, routed to you automatically. Free for everyone right now · no card · nothing to buy

This score summarizes SEC Form 4 filing activity over the trailing 90 days. It is descriptive, not predictive — not a rating, recommendation, or investment advice. Data: SEC EDGAR (public domain), as filed; amendments may revise figures. Tradune is not a registered investment adviser.

Data as filed; amended filings (Form 4/A) may revise figures. Sales may occur under prearranged Rule 10b5-1 trading plans.